US › Healthcare

Nexalin Technology Inc. (NXL)

US · Healthcare · Medical Devices

$5.10+3.64%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$12,161

Revenue YoY

-82.8%

Net profit

$-2.2M

EPS

$-0.11

EPS estimate

$-0.10

Net margin

-18,412.7%

EPS came in at -0.11 against a street estimate of -0.10 — a miss of 10.0%.

Key statistics

Market cap

$4.0M

Forward P/E

0.0

P/B

2.66

Book value

$2.07

EPS (TTM)

$-13.80

52-week high

$60.00

52-week low

$4.51

50-day MA

$10.39

200-day MA

$14.72

Beta

3.98

Analyst view

Analysts rate Nexalin Technology Inc. a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $60.00.

Shareholding

Insiders

19.01%

Institutions

3.45%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.12%
Vanguard Capital Management, LLC	0.57%
Vanguard Fiduciary Trust Co	0.23%
State Street Corp	0.15%
Northern Trust Corp	0.11%
HRT FINANCIAL LLC	0.11%
Kovack Advisors Inc	0.11%
StoneX Group Inc	0.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nexalin Technology Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.